"Baxter International (BAX) benefits from a robust balance sheet, solid operating momentum, and rising earnings estimates," says blue chip advisor Richard Moroney in Dow Theory Forecasts.

The advisor explains, "The first company to commercially prepare intravenous treatments, Baxter has manufactured and distributed medical products since 1931. It primarily works with blood and plasma, a business with recession-resistant tendencies.

"Its BioScience unit produces clotting agents for hemophilia and biotech drugs that treat both immune deficiencies and cancer.

Continue reading Baxter (BAX): Bank on blood products

Baxter (BAX): Bank on blood products originally appeared on BloggingStocks on Tue, 24 Nov 2009 13:30:00 EST. Please see our terms for use of feeds.

Continue reading Baxter's key is versatility

Baxter's key is versatility originally appeared on BloggingStocks on Thu, 22 Oct 2009 15:00:00 EST. Please see our terms for use of feeds.

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Turnaround expert targets laggard pharmaceuticals originally appeared on BloggingStocks on Mon, 12 Oct 2009 12:10:00 EST. Please see our terms for use of feeds.

Continue reading Baxter International (BAX) dips on growth estimates

Baxter International (BAX) dips on growth estimates originally appeared on BloggingStocks on Wed, 16 Sep 2009 13:30:00 EST. Please see our terms for use of feeds.

Baxter (NYSE: BAX) is hosting an analyst day on September 16. BAX closed at $55.60. BAX September option implied volatility of 22 is near its 26-week average of 32 according to Track Data, suggesting decreasing price movement.

Chesapeake Energy (NYSE: CHK) closed at $23.09. Natural gas is recently up 1.32% to 2.844 according to Bloomberg. CHK September option implied volatility is at 45, October is at 47; below its 26-week average of 61, according to Track Data, suggesting decreasing price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Options Update: Baxter volatility low at 22 into analyst day originally appeared on BloggingStocks on Wed, 09 Sep 2009 08:00:00 EST. Please see our terms for use of feeds.

The earnings crunch ramps up this week, and again expectations are generally low. Among the so-called bellwethers that are expected to report lower earnings year over year are CSX Corp. (NYSE: CSX), Gannett Inc. (NYSE: GCI), General Electric Co. (NYSE: GE), Harley Davidson Inc. (NYSE: HOG), Intel Corp. (NASDAQ: INTC), International Business Machines Corp. (NYSE: IBM), Johnson & Johnson (NYSE: JNJ), Marriott International Inc. (NYSE: MAR), Mattel Inc. (NYSE: MAT), Nokia Corp. (NYSE: NOK), and Yum! Brands Inc. (NYSE: YUM). Analysts surveyed by Thomson Reuters do expect the profits of CSX, Gannett, Mattel, and Nokia to be up from the previous quarter, however.

A number of financial companies, big and small, are scheduled to report second-quarter earnings this week, providing a good look at what's going on in the sector. Perhaps the best news will be coming from Citigroup and Marshall & Ilsley. While they are expected to post further losses, at least they are headed in the right direction by narrowing those losses year over year.

Continue reading The week in preview: Another tough quarter for the big banks

The week in preview: Another tough quarter for the big banks originally appeared on BloggingStocks on Sun, 12 Jul 2009 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Don't fear the swine flu . . . trade it

Don't fear the swine flu . . . trade it originally appeared on BloggingStocks on Mon, 27 Apr 2009 13:00:00 EST. Please see our terms for use of feeds.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Abbott Laboratories (NYSE: ABT) Q1 profit edged past expectations despite lower sales of Humira.
• AMR Corp. (NYSE: AMR) posted a smaller-than-expected Q1 loss, sending shares sharply higher.
• Baxter International Inc. (NYSE: BAX) reported better-than-expected Q1 earnings, sending share higher.
• BP (NYSE: BP) and other oil companies were downgraded due to higher environmental costs.
• Charles Schwab Corp. (NASDAQ: SCHW) Q1 earnings declined but still topped analysts' expectations.
• Chevron Corp. (NYSE: CVX) said Q1 earnings would be lower due to a weaker dollar and lower oil prices.

Continue reading Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more originally appeared on BloggingStocks on Sat, 18 Apr 2009 12:10:00 EST. Please see our terms for use of feeds.

Continue reading Baxter (BAX) Q1 earnings beat estimates

Baxter (BAX) Q1 earnings beat estimates originally appeared on BloggingStocks on Thu, 16 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

Continue reading Baxter is one company that's on the mend

Baxter is one company that's on the mend originally appeared on BloggingStocks on Fri, 13 Mar 2009 10:30:00 EST. Please see our terms for use of feeds.

Ted Allrich is the founder of The Online Investor and author of the book: Comfort Zone Investing: Build Wealth and Sleep Well at Night. In this weekly column, he'll offer advice to investors who are just getting started.

For a better investing year in 2009, think about championship basketball. Winners at every level have one thing in common: defense. It's defense that wins rings. And this year, in the stock market, defense will keep you alive. It will be the kind of year where making a little money makes you a winner. Think defensively until there are clear signs that the economy is improving.

First, keep your expectations low. No one knows when the current economic cycle will end and begin to heal. What we do know is that all indicators keep going lower: housing starts, employment, consumer spending, housing prices. While the market discounts good news well in advance (some 6 to 9 months ahead of the real numbers), there's no indication from any front that better days are ahead. We know the new administration will spend money to create jobs so more spending power will be in the economy. We know there will most likely be tax breaks for companies to encourage production and hiring. But none of that is in place. Investors have to wait and see how and if these develop and what effect they will have on the economy and on stocks. It might take all year. Or longer. If it does, the stock market won't be doing too much.

Continue reading Comfort Zone Investing: Six smart ideas for stocks in 2009

Comfort Zone Investing: Six smart ideas for stocks in 2009 originally appeared on BloggingStocks on Sat, 27 Dec 2008 10:30:00 EST. Please see our terms for use of feeds.

Amgen (NASDAQ: AMGN) is a biotechnology firm engaged in the discovery and manufacture of human therapeutics. It markets products in the areas of supportive cancer care, nephrology, inflammation, and metabolic diseases. Principal offerings include anemia treatments Aranesp and Epogen, rheumatoid arthritis drug Enbrel, and white blood cell stimulator Neupogen. Amgen has marketing alliances with Hoffmann-La Roche and Kirin. Baxter International (NYSE: BAX), Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS) and major competitors.

The company pleased the Street late last month, when it announced Phase 3 trial results showing that its experimental osteoporosis drug significantly reduced the risk of bone fractures in post-menopausal women. As well, the firm reported Q2 EPS of $1.14 and revenues of $3.76 billion. Both measures topped consensus Street estimates ($1.02, $3.58 billion). Management also guided FY08 EPS to $4.25-$4.45 ($4.19 consensus) and FY08 revenues to $14.6-$14.9 billion ($14.42B consensus). Eight brokerages subsequently declared AMGN a "buy" and issued price targets in the range $67-$80.

Continue reading Amgen (AMGN): Share price defines bullish 'pennant' formation

Amgen (AMGN): Share price defines bullish 'pennant' formation originally appeared on BloggingStocks on Tue, 05 Aug 2008 10:15:00 EST. Please see our terms for use of feeds.

As the second quarter earnings crunch begins in earnest this week, the bear market has investors jittery and prognosticators spinning out dire warnings. In the wake of mixed results from Alcoa (NYSE: AA) and General Electric (NYSE: GE) kicking things off last week, here's a look at what Wall Street is expecting from many of the companies scheduled to report this coming week.

Analysts surveyed by Thomson Financial are expecting the following companies to report a rise in earnings when compared to the same period of the previous year.

• Nucor Corp. (NYSE: NUE): $1.80 EPS (36.6%) on sales of $6.4 billion (+53.0%)
• Google Inc. (NASDAQ: GOOG): $4.74 EPS (24.9%) on sales of $3.9 billion (+41.6%)
• Nokia Corp. (NYSE: NOK): 56 cents EPS (23.2%) on sales of $19.9 billion (+17.8%)
• CSX Corp. (NYSE: CSX): 90 cents EPS (21.1%) on sales of $2.9 billion (+12.8%)
• Altera Corp. (NASDAQ: ALTR): 27 cents EPS (18.5%) on sales of $346.7 million (+8.4%)
• IBM (NYSE: IBM): $1.82 EPS (+17.6%) on sales of $25.9 billion (+9.0%)
• eBay Inc. (NASDAQ: EBAY): 41 cents EPS (17.1%) on sales of $2.2 billion (+18.0%)
• W.W. Grainger Inc. (NYSE: GWW): $1.46 EPS (17.1%) on sales of $1.7 billion (+8.0%)
• Microsoft Corp. (NASDAQ: MSFT): 47 cents EPS (17.0%) on sales of $15.7 billion (+17.0%)
• Honeywell International Inc. (NYSE: HON): 94 cents EPS (17.0%) on sales of $9.2 billion (+7.9%)

Continue reading The week in preview: Expectations as the earnings crunch begins

The week in preview: Expectations as the earnings crunch begins originally appeared on BloggingStocks on Sun, 13 Jul 2008 12:30:00 EST. Please see our terms for use of feeds.

Edwards Lifesciences Corporation (NYSE: EW) provides products and technologies designed to treat cardiovascular diseases. Offerings include tissue heart valves, valve repair products, heart monitoring equipment, central venous access devices and cardiac surgery system products. The company sells its goods through a direct sales force and independent distributors worldwide. Formerly part of Baxter International (NYSE: BAX), the firm was a year 2000 spin-off.

Edwards surprised the Street late last month, when it reported Q1 EPS of 56 cents and revenues of $296.8 million. Analysts had been expecting 49 cents and $284.4 million. In discussing the results, the CEO noted the success of new products and strong international sales growth. Management also guided Q2 EPS to 62-66 cents (58 cent consensus), FY08 EPS to $2.45-$2.53 ($2.35 consensus) and FY08 revenues to $1.210-$1.260 billion ($1.18B consensus).

Continue reading Edwards Lifesciences (EW): Price cycles in bullish 'flag' formation

Edwards Lifesciences (EW): Price cycles in bullish 'flag' formation originally appeared on BloggingStocks on Fri, 16 May 2008 12:48:00 EST. Please see our terms for use of feeds.

The blood thinner Heparin, used for surgery and dialysis has now killed 81 people in the US. According to The New York Times, "The F.D.A. has identified 12 Chinese companies that have supplied contaminated heparin to 11 countries." The contamination that caused the problems appears to come from manufacturers in China.

The news reopens the question of who is at fault when China ships bad products to the US. Companies like Mattel (NYSE: MAT) and Baxter (NYSE: BAX), a big heparin supplier, would like to blame the Chinese. Alternatively, they could say that the FDA does not have enough inspectors to keep up with drug components imported from the big Asian country.

But all of that is a dodge. Any company that sells a product should ultimately be responsible for that product's safety no matter what the current law says. Baxter makes the money on heparin, why should another entity be responsible for making sure its is safe?

Baxter might argue that it cannot sell heparin at a profit if all of the inspection responsibility falls to it. If so, it should exit the business and leave it to a company that can. All of those people who died would probably agree.

Douglas A. McIntyre is an editor at 247wallst.com

Baxter International (BAX) faces more heparin problems originally appeared on BloggingStocks on Tue, 22 Apr 2008 13:00:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• This year, the International Trade Commission is set to issue rulings on whether Samsung and Nokia Corporation (NYSE: NOK) have infringed patents from InterDigital Inc (NASDAQ: IDCC). If InterDigital, who licenses its patents to iPhone maker Apple Inc (NASDAQ: AAPL), wins, fees from the deals could double its revenue over the next few years, the Wall Street Journal contended.
• The Wall Street Journal also reported that Macy's Inc (NYSE: M) is among the retailers that include The Home Depot Inc (NYSE: HD) and Sears Holdings Corporation (NASDAQ: SHLD) to stop making its monthly disclosure of retail sales.

• According to FDA commissioners, the New York Times reported that Baxter International Inc's (NYSE: BAX) critical blood thinner heparin, which has been linked to nearly 20 deaths and whose base was created in China, contained a "possibly counterfeit" ingredient that "mimicked the real drug."
• In his opening arguments in the state of Alaska's lawsuit against Eli Lilly & Company (NYSE: LLY), an attorney for the state alleged the drug maker failed to warn doctors and patients of dangerous side effects associated with its drug Zyprexa, the Associated Press reported.

Newspaper wrap-up: Patent win may boost multimedia phone supplier originally appeared on BloggingStocks on Thu, 06 Mar 2008 08:00:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• The Wall Street Journal reported that the focus of reports of four deaths and 350 allergic reactions to Baxter International Inc's (NYSE: BAX) generic version of the blood thinner drug Heparin, and the ingredients supplied by a Chinese manufacturer, also includes Wisconsin-based Scientific Protein Laboratories, a co-owner of the Chinese manufacturing plant, and majority owned by American Capital Strategies Ltd (NASDAQ: ACAS), a Maryland buyout firm.
• Citigroup Incorporated (NYSE: C) has suspended investors at its CSO Partners hedge fund from withdrawing their money after they attempted to pull more than 30% of the fund's nearly $500M in assets, the Wall Street Journal reported.
• AT&T Inc (NYSE: T) is seeking more revenue from India as it tries to expand its consumer mobile phone operations outside the U.S, the Financial Times reported.

• According to the New York Times, the FDA broke its own rules by approving for sale Baxter International's Heparin without first inspecting a Chinese plant where the drug's key ingredient is made.

Newspaper wrap-up: American Capital Strategies tied to Baxter's Heparin generic problems originally appeared on BloggingStocks on Fri, 15 Feb 2008 08:00:00 EST. Please see our terms for use of feeds.

Continue reading Before the bell: MAR, UBS, BA, TASR, LIZ, BAX, HPQ

Before the bell: MAR, UBS, BA, TASR, LIZ, BAX, HPQ originally appeared on BloggingStocks on Thu, 14 Feb 2008 08:40:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• The active ingredient in Baxter International Inc's (NYSE: BAX) generic version of the anticlotting drug heparin, under investigation for four deaths and hundreds of bad reactions, was made in China, the Wall Street Journal reported.
• Structured investment vehicles that provide short term debt to fund the purchases of municipal bonds and student loans are under increasing pressure, according to the Wall Street Journal's "Heard on the Street". Citigroup Incorporated (NYSE: C), JP Morgan Chase & Co (NYSE: JPM) and Merrill Lynch & Co Inc (NYSE: MER) are among the banks that could be affected.

• The New York Times reported that Hewlett-Packard Company (NYSE: HPQ) has settled with The New York Times Company (NYSE: NYT) and McGraw Hill Companies Incorporated's (NYSE: MHP) BusinessWeek journalists related to a spying scandal that stemmed from obtaining telephone records. The involved parties did not disclose the amount of the settlement.

• Mike Zafirovski, CEO of Nortel Networks Corporation (NYSE: NT), said the company would examine possible opportunities to be taken over "when they arise." Mr. Zafirovski did not comment on rumors of a Motorola Inc (NYSE: MOT) merger, Reuters reported.

Newspaper wrap-up: Investigated ingredient in Baxter's generic heparin drug made in China originally appeared on BloggingStocks on Thu, 14 Feb 2008 08:00:00 EST. Please see our terms for use of feeds.

A plant in China may be producing flawed ingredients for the big-selling Baxter International (NYSE:BAX) blood thinner Heparin. According to The Wall Street Journal, it is the same "blood-thinner that is under investigation after reports of hundreds of allergic reactions and four deaths among the drug's users."

While the FDA failed to inspect that facility, it is Baxter's responsibility to ensure the safety of its own products. The debacle is not unlike the one that plagued Mattel (NYSE: MAT) last year when it was importing toys from China that contained high levels of lead. In Baxter's case, however, it appears that people have lost lives.

Baxter and the FDA now probably face months of criticism, much of it coming from Congress, which is already concerned about the quality of China-made products.

Baxter also needs to worry about whether it will be viewed as having any liability in the cases where Heparin caused illness. It looks like a trial lawyer's dream.

Douglas A. McIntyre is an editor at 247wallst.com

China quality problems may make Baxter (BAX) the next Mattel (MAT) originally appeared on BloggingStocks on Thu, 14 Feb 2008 04:45:00 EST. Please see our terms for use of feeds.